ImClone Investigational Site

New York, New York 10065

0 studies enrolling now · 21 studies all time

What they study most

Adenocarcinoma, Breast Cancer, Colorectal Cancer, Colorectal Neoplasms, Fallopian Tube Neoplasms, Gastric Cancer, Head and Neck Cancer, Hepatocellular Carcinoma, Malignant Melanoma, Metastatic Breast Cancer, Metastatic Malignant Melanoma, Non Small Cell Lung Cancer

Studies at this site

• First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin — Completed
• Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer — Completed
• Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma — Completed
• A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma — Completed
• Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients — Completed
• An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma — Completed
• A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer — Completed
• Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy — Completed
• A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver — Completed
• A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before — Completed
• Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck — Completed
• A Study of Olaratumab in Soft Tissue Sarcoma — Completed
• A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib — Completed
• A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer — Completed
• A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer — Completed
• A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma — Completed
• Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer — Completed
• A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma — Stopped early
• Study of gp75 Vaccine in Patients With Stage III and IV Melanoma — Completed
• A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer — Completed
• Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer — Completed